Follicular Lymphoma
Diminutio
Dodging potholes from cancer care to hospice transitions
The consequences of suboptimal hospice transitions can damage the mental health and well-being of patient and caregiver.
Diminutio
“I didn’t want to meet you.” Dispelling myths about palliative care
This is the first installment of “Diminutio,” a column by Sarah D’Ambruoso, NP, a palliative care nurse in oncology. Today, she shares stories...
Conference Coverage
‘Outstanding data’: Mosunetuzumab in r/r follicular lymphoma
If approved by the FDA, mosunetuzumab has the potential to be a first-in-class CD20xCD3 T-cell engaging bispecific antibody in non-Hodgkin...
Conference Coverage
Many patients, doctors unaware of advancements in cancer care
“These patients must be spared the traumatic effects of being handed a death sentence that no longer reflects the current reality,” said Dr....
From the Journals
Immunotherapy for cancer patients with poor PS needs a rethink
Patients should not receive immunotherapy just to reduce risk of side effects, doctor says.
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
From the Journals
New inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible inhibitor.
Conference Coverage
Novel ddPCR assay precisely measures CAR T-cells after infusion
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
News from the FDA/CDC
FDA gives thumbs up to tazemetostat for follicular lymphoma
From the Journals
Lymphocyte, monocyte data can predict treatment response in follicular lymphoma
Blood cell count values at diagnosis can predict the clinical outcomes in follicular lymphoma.